



Neuland Laboratories Limited
11th Floor (5th Office Level),
Phoenix IVY Building,
Plot No.573A-III, Road No.82,
Jubilee Hills, Hyderabad - 500033,
Telangana, India.

Tel: 040 67611600 / 67611700
Email: neuland@neulandlabs.com
www.neulandlabs.com

April 1, 2022

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Declaration under Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Please find enclosed declaration in compliance with Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is for your information and records.

Yours faithfully,

For Neuland Laboratories Limited

Sarada Bhamidipati
Company Secretary

Encl: As above

Davuluri Rama Mohan Rao

*Plot no.378, Road no.10,
Jubilee Hills, Shaikpet,
Jubilee Hills, Hyderabad
500033 TG IN*

April 1, 2022

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001
Scrip Code: 524558

To
The National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai - 400 001
Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,

Sub: Declaration under Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

With reference to captioned subject, please find enclosed disclosures under Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

This is for your information and records.

Yours sincerely,



Dr. Davuluri Rama Mohan Rao

CC: The Company Secretary, Neuland Laboratories Limited
11th Floor (5th Level), Phoenix IVY Building,
Plot No. 573A-III, Road No. 82, Jubilee Hills,
Hyderabad, 500033, Telangana, India

Format for disclosure by the Promoter(s) to the stock exchanges and to the Target Company for encumbrance of shares / invocation of encumbrance/ release of encumbrance, in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company(TC)		Neuland Laboratories Limited												
Names of the Stock Exchanges where the shares of the target company are listed		1. BSE Limited 2. The National Stock Exchange of India Ltd												
Date of reporting		April 1, 2022												
Name of the promoter or PAC on whose shares encumbrance has been created/released/invoked		Dr. Davuluri Rama Mohan Rao												
Details of the creation/invocation/release of encumbrance:														
Name of the promoter (s) or PACs with him(**)	Promoter holding in the target company (1)			Promoter holding already encumbered (2)			Details of events pertaining to encumbrance (3)					Post event holding of encumbered shares {creation [(2)+(3)]/release [(2)-(3)]/ invocation [(2)-(3)]}		
	No. of shares	% of total share capital	% w.r.t diluted share capital(*)	No. of shares	% of total share capital	% of total share capital	Type of event (creation /release /invocation)	Date of creation/ invocation release of encumbrance	Type of encumbrance (pledge/ lien/ non disposal undertaking / others)	No. of shares	% of total share capital		Name of the entity in whose favor shares encumbered	
Dr. Davuluri Rama Mohan Rao	32,03,474	24.97%	24.97%	2,00,000	1.56%	1.56%	Release	March 29, 2022	Pledge	2,00,000	1.56%	State Bank of India	NIL	NIL

Signature of the Authorized Signatory:

Place : Hyderabad

Date : 1-April-2022

(**) The names of all the promoters, their shareholding in the target company and their pledged shareholding as on the reporting date should appear in the table irrespective of whether they are reporting on the date of event or not.

(*) Total share capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

